Elite Pharmaceuticals Inc (ELTP)

[jour_trader]

Acquisition price will depend on how far out they go to determine the terminal value. Is it 3 years, is it 5 years? We simply don't know. Even 3 years out, I'd expect Eliquis to be a huge money maker for the first year and then will taper off and still be a solid addition to our portfolio. Using estimated revenues in 2028 and DCF back to today, Vyvanse holds tremendous opportunity - no doubt about it. 
The big question is how much more is it discounted since we don't have an ANDA filed or approved?
10% of a $2.7B drug (assume after stabilization) is $270M top line annually after launch ramp up. Back of the envelope, take 30% as flow through and throw on a conservative EBITDA multiple. Now discount back a few years. Even just one year of no quota hurdle would be sweet to see executed.